Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives

Dow Jones

07/18

Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.

The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.

Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.

Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.

"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees," the company said in its filing.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

July 17, 2026 18:14 ET (22:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2652233925"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652233925\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652233925?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-18 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652233925","market":"fut","top_or_hot":-1,"title":"Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company launched a cash-retention program for executives. \n</p>\n<p>\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n</p>\n<p>\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n</p>\n<p>\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 18:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-18 06:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company launched a cash-retention program for executives. \n</p>\n<p>\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n</p>\n<p>\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n</p>\n<p>\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 18:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652233925","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652233925","pubTimestamp":1784326440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.\"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing.Write to Elias Schisgall at elias.schisgall@wsj.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KPTI":"Karyopharm Therapeutics Inc."},"translate_title":"Karyopharm Therapeutics 关于披露高管现金保留计划的幻灯片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":1.5},"content_text":"Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives. \n\n\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n\n\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n\n\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n\n\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2026 18:14 ET (22:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}